

H.R. 1781, Payment Commission Data Act of 2019

As ordered reported by the House Committee on Energy and Commerce on April 3, 2019

Millions of Dollars	2019	2019-2024	2019-2029
Direct Spending (Outlays)	0	0	0
Revenues	0	0	0
Deficit Effect	0	0	0
Spending Subject to Appropriation (Outlays)	0	*	*
Pay-as-you-go procedures apply?	No	Mandate Effects	
Increases on-budget deficits in any of the four consecutive 10-year periods beginning in 2030?	No	Contains intergovernmental mandate?	No
		Contains private-sector mandate?	No
* = less than \$500,000			

H.R. 1781 would grant the Medicare Payment Advisory Commission (MedPAC) and the Medicaid and CHIP Payment and Access Commission (MACPAC) access to data about prescription drug spending and utilization in the Medicare Part D program. MedPAC and MACPAC would be prohibited from identifying specific drug prices or discounts revealed by the data.

The bill would not affect spending for drugs or other services in either Medicare or Medicaid; therefore, CBO estimates that H.R. 1781 would not affect direct spending or revenues. MedPAC and MACPAC might have to increase spending on information technology (IT) to ensure that the data are secure. Any such spending would be insignificant and subject to appropriation.

The CBO staff contacts for this estimate are Rebecca Yip and Lara Robillard. The estimate was reviewed by Leo Lex, Deputy Assistant Director for Budget Analysis.